ReNeuron shares positive data from Phase 1/2a hRPC stem cell study
Category: #health  By Pankaj Singh  Date: 2020-02-25
  • share
  • Twitter
  • Facebook
  • LinkedIn

ReNeuron shares positive data from Phase 1/2a hRPC stem cell study

ReNeuron Group plc, a UK based pharmaceutical firm that specializes in cell-based therapeutics, has recently announced encouraging long-term data from its Phase 1/2a clinical study of hRPC stem cell therapy in RP (retinitis pigmentosa).

Currently, ReNeuron is planning to expand this ongoing trial. Retinitis pigmentosa is basically a group of eye-related hereditary disease that could lead to blindness or progressive loss of sight in patients.

Earlier in October 2019, the company had released encouraging interim efficacy data from the Phase 2a segment’s treated patients of the ongoing Phase 1/2 trial. Moreover, this data was presented at San Francisco’s American Academy of Ophthalmology Meeting by Dr. Pravin Dugel.

Reportedly, the data revealed a cohort of patients who had a positive surgical procedure with constant clinically relevant developments in visual acuity, when assessed against baseline results.

Speaking on the move, Olav Hellebø, Chief Executive Officer, ReNeuron, said that the company is encouraged by these positive data from its Phase 1/2a clinical trial for retinitis pigmentosa patients. Evidently, follow-up data is exceptionally noteworthy in this case, proving that the treatment successfully maintains its favorable effects for at least one year after treatment.

Prior to this news, ReNeuron had made headlines when it announced that its clinical data from the PISCES II Phase 2a clinical study of CTX stem cell treatment for patients suffering from disability after going through stroke, would be published in a peer-reviewed journal.

Sources cite that results from the trial were initially presented at the American Heart Association International Stroke Conference 2018 by Professor Keith Muir in January 2018. Data from this trial can be found online in the Journal of Neurology, Neurosurgery, and Psychiatry (JNNP).

Upon which, CEO Hellebø commented that the company is pleased to see such encouraging data from the PISCES II clinical study of CTX cell therapy being published in a highly regarded peer-reviewed journal.

Source Credit: https://www.prnewswire.com/news-releases/reneuron-announces-positive-long-term-data-in-retinal-clinical-trial-301010085.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

TikTok to donate 4 Lakh safety suits to Indian healthcare workers
TikTok to donate 4 Lakh safety suits to Indian healthcare workers
By Pankaj Singh

Amidst lowering availability of medical equipment and safety gear in India during the current COVID-19 crisis, Chinese video-sharing company, TikTok has made a generous gesture by announcing that it will donate ab...

Inzomelid declares positive CAPS treatment results, completes Phase I
Inzomelid declares positive CAPS treatment results, completes Phase I
By Pankaj Singh

Inflammasome biotech company Inflazome has reportedly announced the successful completion of Inzomelid’s Phase I clinical study. In addition, the firm has also declared that it has observed positive results from ...

Flipkart to re-open its online portal to deliver essential products
Flipkart to re-open its online portal to deliver essential products
By Pankaj Singh

Flipkart, a renowned Indian e-commerce company, reportedly announced that it would be re-starting its online portal to deliver essential commodities across India. The company had closed down all its operations on Wedne...